Extended Data Fig. 1 | Nature Medicine

Extended Data Fig. 1

From: Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study

Extended Data Fig. 1

Study design. aATI planned for 12 weeks; ART-restart criteria were ≥1 of the following: ≥2 consecutive plasma HIV-1 RNA measures ≥1000 copies/mL for ≥4 weeks; ≥2 consecutive measures of >30% decline from baseline CD4 + T cell count or absolute CD4 + T cell count <350 cells/µL; HIV-associated symptoms, including symptoms of retroviral rebound syndrome; pregnancy; or participant or investigator request to reinitiate ART. ART, antiretroviral therapy; ATI, analytical treatment interruption; IV, intravenous; PBO, placebo.

Back to article page